Products for Research Use Only
RegisterLogin

Regorafenib (Standard)

CAT: 0804-HY-10331R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10331R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity[1].
CAS Number
755037-03-7
Product Name Alternative
BAY 73-4506 (Standard)
UNSPSC
12352005
Target
Autophagy; c-Kit; FGFR; PDGFR; Raf; Reference Standards; RET; Tie; VEGFR
Type
Reference Standards
Related Pathways
Autophagy; MAPK/ERK Pathway; Others; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/regorafenib-standard.html
Smiles
O=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F
Molecular Formula
C21H15ClF4N4O3
Molecular Weight
482.82
References & Citations
[1]Wilhelm SM, et al. Regorafenib (BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129 (1), 245-255.|[2]Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2 (1), 39-49.|[3]Carr BI, et al. Fluoro-Bay 43-9006 (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228 (2), 292-297.|[4]Wagner J, et al. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. J Exp Clin Cancer Res. 2018 Jan 22;37 (1) :11.|[5]Matsuoka K, et al. Effective Sequential Combined Chemotherapy with Tipiracil and Regorafenib in Human Colorectal Cancer Cells. Int J Mol Sci. 2018 Sep 25;19 (10) . pii: E2915.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Related Products

CatalogName
HY-10331AR-01Regorafenib (monohydrate) (Standard)
HY-13308R-01Regorafenib (Hydrochloride) (Standard)
HY-10331-01Regorafenib
HY-10331BRegorafenib (mesylate)
HY-13308-01Regorafenib (Hydrochloride)
HY-10331A-01Regorafenib (monohydrate)
HY-10331S-01Regorafenib-d3
HY-I0669-01Regorafenib impurity 1
HY-I0677-01Regorafenib impurity 8
HY-10331S1-01Regorafenib-13C, d3

Alternative Products

CatalogName
A8236-50Regorafenib

Popular Products